POSTER SESSION 1: Biomarkers

P1.1 Do plasma miRNAs have a role before and after treatment in colorectal cancer?
Lava Kannappa, Ehdode Abdlrzag, James Howard Pringle, Baljit Singh 

P1.2 Prognostic factors of overall survival benefit in patients treated by PD-1/PD-L1 inhibitors: retrospective analysis of 128 phase 1 patients
Pauline du Rusquec, Edouard Auclin, Ronan Flippot, Christophe Massard, Antoine Hollebecque, Emilie Lanoy, Xavier Paoletti, Jean-Charles Soria, Sophie Postel-Vinay

P1.3 Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib
Aline Houessinon, Catherine Francois, Christophe Louandre, Antoine Galmiche

P1.4 Alfa-feto protein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib
Aline Houessinon, Albane Gicquel, Flora Bochereau, Christophe Louandre, Remy Nyga, Zuzana Saidak, Jean Claude Barbare, Bruno Chauffert, Catherine Francois, Olivier Pluquet, Antoine Galmiche

 

POSTER SESSION 2: New molecular targets

P2.1 Blocking the stress specific APIM-PCNA interactions increases the efficacy of cancer therapies
Marit Otterlei, Caroline D. Søgaard, Augun Blindheim, Anala Nepal, Voin Petrovic, Lisa M. Rost, Siri Backhe, Camilla Olaisen, Odrun A. Gederaas, Carl-Jørgen Arum, Tonje S. Steigedal, Per Bruheim

P2.2 Targeted therapy of human glioblastoma via delivery of a protein toxin through surface directed peptides
Anne-Choé Dhez, Elisabetta Benedetti, Francesco Giansanti, Annamaria Cimini, José Courty, Rodolfo Ippoliti

P2.3 The selective inhibitor of nuclear export compound selinexor inhibits NF-κB and induces anti-non-small cell lung cancer activity
Marsha Crochiere, William Senapedis, Trinayan Kashyap, Dilara McCauley, Michael Kauffman, Sharon Shacham, Yosef Landesman

P2.4 Ketotifen  a mast cell stabilizer  modulates exosome/doxorubicin release from cancer cells
Raafat El-Awady, Farman Khan, Ekram Saleh

 

POSTER SESSION 3: Preclinical drug profiles

P3.1 Guadecitabine (SGI-110)  a novel partner in immunotherapy
Pietro Taverna, James Lowder, Harold Keer, Alessia Covre, Anna Maria Di Giacomo, Mohammad Azab, Michele Maio

P3.4 MerTK or Axl inhibition enhances sensitivity to EGFR TKIs in NSCLC cell lines expressing wild-type or mutant EGFR
Dan Yan, Christopher Cummings, Xiaodong Wang, Stephen Frye, Shelton Earp, Deborah DeRyckere, Douglas Graham

P3.5 ASN003  a highly selective inhibitor of BRAF and PI3K kinases  shows strong antitumor activity in melanoma and colon cancer xenograft models
Sanjeeva Reddy, Mahaboobi Jaleel, Vijay Kumar Nyavanandi, Murali Ramachandra Ramachandra, Hosahalli Subramanya, Aravind Basavaraju, Vaibhav Shirorkar, Roger Smith, Niranjan Rao, Scott Thompson

P3.7 The effects of pharmacological targeting of mutant p53 by PRIMA-1MET combined with ionizing radiation in glioblastoma cells in vitro
Mariia Patyka, Siham Sabri

P3.8 Combinatorial siRNA polyplex for folate receptor-directed gene silencing efficiency and tumor targeting
Dian-Jang Lee, Dongsheng He, Eva Kessel, Ernst Wagner

P3.9 Antiproliferative activity  DNA damage and cell cycle effect of new 5-aminosalicylates 4-thiazolinone hybrid derivatives
Ekram Saleh, Raafat El-Awady, Abdel Naser El-Shorbagi, Hajjaj Abdu-Allah 

 

POSTER SESSION 4: Clinical studies

P4.1 A phase I study of the CDK4/6 inhibitor  palbociclb (palbo) plus 5-fluorouracil (5FU) in patients with advanced solid tumor malignancies
Michael J. Pishvaian, Hongkun Wang, Brandon Smaglo, Laura Macke, Erica Redmond, Stephen V. Liu, Aiwu Ruth He, Deepa Subramaniam, Jimmy Hwang, Damian McCarthy, John L. Marshall, Paula R. Pohlmann

P4.3 A phase 1 study of CRLX301  a novel Nanoparticle-Drug Conjugate (NDC) containing docetaxel  in patients with refractory solid tumors
Hongwei Wang, Ben Markman, Paul DeSouza, E. Claire Dees, Tara Gangadhar, Adam Cooper, Aflah Roohullah, William Zamboni, Scott Eliasof, Curran Murphy, Adrian Senderowicz

P4.4 A phase I study of metformin in combination with cisplatin and radiation in locally advanced head and neck squamous cell carcinom
Trisha Wise-Draper, Vinita Takiar, Michelle Mierzwa, Bradley Huth, Kevin Redmond, William Barrett, Julianne Qualtieri, Changchun Xie, John Morris, J. Silvio Gutkind, Nooshin Hashemi Sadrei

P4.5 A phase I trial of a pharmacodynamically-conceived decitabine/thioguanine combination in patients with advanced myeloid malignancies
Todd Rosenblat, Mark Heaney, Joseph Jurcic, Azra Raza, Katherine Harwood, Ryan Shelton, Kristina Gazivoda, Hakim Djaballah, Joseph Scandura, Anthony Letai, Mark Frattini

P4.6 Patient-reported tolerability of adverse events in phase I trials: a patients’ based DLT-TARGETT survey
Clémence Henon, Delphine Lissa, Aicha Goubar, Constance Thibault, Emilie Lanoy, Christophe Massard, Jean-Charles Soria, Sophie Postel-Vinay

P4.7 Phase 2  randomized trial (RADIUS): standard of care ± midostaurin after allogeneic stem cell transplant in FLT3-ITD–mutated AML
Richard Maziarz, Mrinal Patnaik, Bart Scott, Sanjay Mohan, Abhinav Deol, Kelly Haines, Brian Elliott, Hugo Fernandez 

P4.9 Molecular profiling of patients with breast cancer for tractable targets in an Asian tertiary cancer centre
Tira Tan, Chen Wei Pow, Yoon Sim Yap, Elaine Lim, Rebecca Dent, David Tai, Matthew Ng, Gek San Tan, Sai Sakktee Krisna, Tony Lim, Daniel Tan

POSTER SESSION 5:  Translational studies

P5.1 Angiogenic potential of erythropoietin and the role of erythropoietin receptor in lung cancer cells
Rudolf M. Dr. Huber, Xiaoqing Liu, Rosemarie Kiefl

P5.2 Quantitative HER2 protein expression analysis in multiple cancer indications
Shankar Sellappan, Sarit Schwartz, Fabiola Cecchi, Adele Blackler, Patrick Soon-Shiong, Shahrooz Rabizadeh, Todd Hembrough

P5.3 Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab penetrates tumors and shows antitumor activity in patients
Patrice Douillard, Michael Thiele, Alexander Schinagl, Niels Halama, Dirk Jaeger, Deyaa R. Adib, Xiaochun Liu, Salim Yazji, Randolf Kerschbaumer, Friedrich Scheiflinger
 

POSTER SESSION 6: Miscellaneous topics

P6.1 Entropy and cancer
Paul Gougis, Andrew E Teschendorff, Martin Forster

P6.2 Opportunities and challenges associated with tackling metastasis
Christopher Ireson, Robin Anderson, Juliana Callaghan, Charles Coombes, Sue Eccles, Jeff Evans, Sally Kinrade, David Jones, Paul Jones, Rob Jones, John Marshall, Robert McLeod, Beatrice Panico, James Ritchie, Jacqui Shaw, Patricia Steeg, Mark Sullivan, Warwick Tong, Andrew Westwell

P6.3 Extremely low invasive control of liposomal drug release with radical pair system under exposure to static magnetic fields
Hidenori Nakagawa, Hiromi Kawase, Mikio Ohuchi, Shoogo Ueno

P6.4 Development of an electromagnetic therapy against intractable cancerous tumors: photomagnetic controls of liposomal DDSs in vitro
Hidenori Nakagawa, Hiromi Kawase, Mikio Ohuchi, Shoogo Ueno


POSTER SESSION: Late Breaking Abstracts

LBA1 The role of LDH as predictive marker of activity in patients with solid tumors treated with anti PD-1 and PDL-1 monoclonal antibodies
Maria Silvia Cona, Valter Torri, Marina Garassino, Massimo Di Nicola, Michele Del Vecchio, Sara Cresta, Diego Signorelli, Matteo Duca, Silvia Damian, Alice Indini, Monica Niger Filippo de Braud

LBA 2 SLFN11 Kills Cancer Cells by Enforcing Irreversible S-phase Arrest through RNA Synthesis Inhibition in Response to DNA Damage
Junko Murai, Sai-Wen Tang, Yves Pommier

LBA 3 GTL002, a novel multivalent antigen-specific immunotherapy targeting human papillomavirus infected women.
Michaël Esquerré, Yolande Misseri, Emmanuelle Totain, Christophe Gonindard, Marie Best, Astrid Navarro, Justine Morato, Hélène Keller, Alain Bousquet-Melou, Séverine Boullier, Marie-Christine Bissery          

LBA 4 Resveratrol inhibits STAT3 signaling pathway through the induction of SOCS-1: Role in apoptosis induction and radiosensitization in head and neck tumor cells
Seung Ho Baek, Jeong-Hyeon Ko, Hanwool Lee, Jinhong Jung, Moonkyoo Kong, Jung-woo Lee, Junhee Lee, Seok-Geun Lee, Bum Sang Shim, Gautam Sethi, Sung-Hoon Kim, and Kwang Seok Ahn